Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12972550 | 0.86 | TSHR (0.61) | TSHRLMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL8925728 | 0.86 | TSHR (0.68) | TSHRLMNAKDM4EALDH1A1KMT2A | |
| Dimethyl Succinate SCHEMBL10213 | 0.81 | TSHR (1.00) | TSHRLMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL755487 | 0.81 | KMT2A (0.39) | TSHRALDH1A1KMT2AHSD17B10MEN1 | |
| Dimethyl Succinate SCHEMBL28054469 | 0.81 | TSHR (1.00) | TSHRLMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL13246470 | 0.81 | RECQL (0.64) | TSHRLMNAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL16017854 | 0.80 | ADRA2A (0.39) | TSHRLMNAALDH1A1KMT2AMAPT | |
| SCHEMBL204758 | 0.79 | GAA (0.50) | TSHRLMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL13188964 | 0.79 | RECQL (0.57) | TSHRLMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL18630155 | 0.78 | TSHR (0.36) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115594627-B | 5-Hydronaphtho [2,3-c ] carbazole dione derivative, preparation method and application | 西华大学 | 2024-10-18 | — | — | CN | disclosed |
| US-11833167-B2 | Nicotinyl riboside compounds and their uses | MITOPOWER LLC (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | MITOPOWER LLC | 2023-08-17 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-27 | — | — | US | disclosed |
| US-9421192-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160067223-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-9174988-B2 | Small molecule inhibitors of hepatitis C virus | TRUSTEES OF BOSTON UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-9029550-B2 | Conformationally restricted urea inhibitors of soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-12 | — | — | US | disclosed |
| US-8188289-B2 | Conformationally restricted urea inhibitors of soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-29 | — | — | US | disclosed |
| US-8153618-B2 | Bridged polycyclic compound based compositions for topical applications for pets | ALLACCEM, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153618-B2 | Bridged polycyclic compound based compositions for topical applications for pets | ALLACCEM, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153617-B2 | Bridged polycyclic compound based compositions for coating oral surfaces in humans | ALLACCEM, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153617-B2 | Bridged polycyclic compound based compositions for coating oral surfaces in humans | ALLACCEM, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110268697-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | disclosed |
| US-7863465-B2 | Antifungal agents | MERCK SHARP & DOHME CORP. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080009504-A1 | Antifungal agents | SCYNEXIS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20070225283-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225283-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067223-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | TSHR 4635/4885LMNA 3159/4885KDM4E 3857/4885 |
| US-20080009504-A1 | Antifungal agents | DPM1, MAN2B1, MAN2A1 | TSHR 4788/4885LMNA 3407/4885KDM4E 3462/4885 |
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | NADK, NNT, NAMPT | TSHR 3343/4885LMNA 800/4885KDM4E 3059/4885 |
| US-20110268697-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | TSHR 4635/4885LMNA 3159/4885KDM4E 3857/4885 |
| US-20070225283-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, NCEH1 | TSHR 3335/4885LMNA 3843/4885KDM4E 1556/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | TSHR 4635/4885LMNA 3159/4885KDM4E 3857/4885 |
| US-11833167-B2 | Nicotinyl riboside compounds and their uses | NADK, NNT, NAMPT | TSHR 3796/4885LMNA 608/4885KDM4E 3520/4885 |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | TSHR 4635/4885LMNA 3159/4885KDM4E 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.